Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 1084-1092

  Sang, Min Lee ^a   Jae, Ho Bae ^a   Mi, Ju Kim ^a   Hyun, Sun Lee ^c   Min, Ki Lee ^b   Byung, Seon Chung ^a   Dong, Wan Kim ^d   Chi, Dug Kang ^a,b   Sun, Hee Kim ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

^c Busan Medical Center   (South Korea)

^d Changwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEAT SHOCK PROTEIN 90; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; IMATINIB; KU ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P300; PROTEIN P53; PROTEIN TYROSINE KINASE; VORINOSTAT;

ACETYLATION; ARTICLE; CELL ISOLATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ACYLATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM PROTEINS; PIPERAZINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; UP-REGULATION;

EID: 34548104621     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.124461     Document Type: Article

References (35)

1. Azam M and Daley GQ (2006) Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 10:67-76.
2. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729-26734.
3. Bandyopadhyay D, Mishra A, and Medrano EE (2004) Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 64:7706-7710.
4. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, and Turner BM (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19:1751-1759.
5. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP, and Young BD (2003) Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39:1165-1175.
6. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, and Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223-229.
7. Chu F, Chou PM, Zheng X, Mirkin BL, and Rebbaa A (2005) Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65:10183-10187.
8. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM, and Sinclair DA (2004) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13:627-638.
9. Dai Y, Rahmani M, Corey SJ, Dent P, and Grant S (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279:34227-34239.
10. Deininger MW, Goldman JM, and Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
11. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, and van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749.
12. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, et al. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64:672-677.
13. Duan H, Heckman CA, and Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25:1608-1619.
14. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
15. Glozak MA, Sengupta N, Zhang X, and Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23.
16. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, and Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
17. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, et al. (2005) Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105:1246-1255.
18. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, and Wu CW (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275:20436-20443.
19. Kikuchi H, Takami Y, and Nakayama T (2005) GCN5: a supervisor in all-inclusive control of vertebrate cell cycle progression through transcription regulation of various cell cycle-related genes. Gene 347:83-97.
20. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isono M, Isshiki K, Uzu T, Kashiwagi A, and Koya D (2006) Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 40:2175-2182.
21. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, and Gambacorti-Passerini C (2000) Induction of resistance to the Abelson inhibitor imatinib in human leukemic cells through gene amplification. Blood 95:1758-1766.
22. Liu T, Kuljaca S, Tee A, and Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32:157-165.
23. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, and Gu W (2001) Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107:137-148.
24. Marks PA and Jiang X (2005) Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4:549-551.
25. Muller C and Salles B (1997) Regulation of DNA-dependent protein kinase activity in leukemic cells. Oncogene 15:2343-2348.
26. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, and Bhalla K (2002) Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 62:5761-5769.
27. Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S, Hoelzer D, Atadja P, Ruthardt M, and Ottmann OG (2004) Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89:419-426.
28. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, and Matsuyama S (2003) Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5:320-329.
29. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, and Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
30. Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, and Miyata N (2005) Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 48:1019-1032.
31. Um JH, Kang CD, Bae JH, Shin GG, Kim do W, Kim DW, Chung BS, and Kim SH (2004) Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells. Exp Mol Med 36:233-242.
32. Wang AG, Kim SU, Lee SH, Kim SK, Seo SB, Yu DY, and Lee DS (2005) Histone deacetylase 1 contributes to cell cycle and apoptosis. Biol Pharm Bull 28:1966-1970.
33. Yoshida C and Melo JV (2004) Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol 79:420-433.
34. + human myeloid leukemia cells. Cancer Res 63:2118-2126.
35. Waf1/Cip1. Mol Cell Biol 26:2782-2790.